The Role of IL-35 in Regulating Tumor Immunity

Junfeng Zhang, Yunsheng Zhang, Chunlei Li, Xiaomei Zhang, Huabao Xiong, Hongxin Deng

Abstract


Interleukin 35 (IL-35) is the newest identified heterodimeric cytokine in the IL-12 cytokine family. IL-35 is a heterodimer comprised of IL-12 subunit alpha (p35) and IL-27 subunit Epstein-Barr virus-induced gene 3 (EBI3). Since discovery, IL-35 showed different immunosuppressive functions from other members of the IL-12 family. It is shown that IL-35 inhibits immune responses by suppressing the differentiation of Th17 cells and macrophages and inhibiting the proliferation and function of effector T cells. Although studies showed that IL-35 has been secreted by regulatory T cells, CD8+ regulatory T cells and regulatory B cells, other studies have also shown that IL-35 may be more widely expressed in cancer cell lines, such as lung adenocarcinoma, hepatocellular carcinoma, cervical carcinoma, breast cancer, and gastric cancer. Recent studies have also shown that IL-35 secreted by tumor cells promotes both tumor growth and metastasis by enhancing the accumulation of angiogenesis and myeloid-derived suppressor cells, and decreasing the infiltration of CD8+ T cells into tumor microenvironment. In this review, the structure and biological functions of IL-35 were reviewed in detail, and the roles of IL-35 in different types of cancers including colorectal cancer, pancreatic ductal adenocarcinoma, acute myeloid leukemia, hepatocellular carcinoma, breast cancer and so on were discussed.

Keywords


Interleukin 35; Cancer; IL-35 signaling; Microenvironment

Full Text:

PDF

References


Motz GT, Coukos G: The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011, 11(10):702-711.

Facciabene A, Motz GT, Coukos G: T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72(9):2162-2171.

Wykes MN, Lewin SR: Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 2018, 18(2):91-104.

Tavakolpour S, Alavian SM, Sali S: Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepat Mon 2016, 16(6):e37927.

Tao Q, Chen T, Tao L, Wang H, Pan Y, Xiong S, Zhai Z: IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. J Immunother 2013, 36(9):462-467.

Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T et al: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017, 551(7680):340-345.

Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M: Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol 2008, 20(9):1189-1199.

Sun B, Zhang Y: Overview of orchestration of CD4+ T cell subsets in immune responses. Adv Exp Med Biol 2014, 841:1-13.

Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE et al: Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016, 127(22):2672-2681.

Sheng J, Chen Q, Soncin I, Ng SL, Karjalainen K, Ruedl C: A Discrete Subset of Monocyte-Derived Cells among Typical Conventional Type 2 Dendritic Cells Can Efficiently Cross-Present. Cell Rep 2017, 21(5):1203-1214.

Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450(7169):566-569.

Collison LW, Vignali DA: Interleukin-35: odd one out or part of the family? Immunol Rev 2008, 226:248-262.

Kastelein RA, Hunter CA, Cua DJ: Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007, 25:221-242.

Ma X, Trinchieri G: Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 2001, 79:55-92.

Molle C, Goldman M, Goriely S: Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J Immunol 2010, 184(4):1784-1792.

Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A, Devergne O: Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008, 181(10):6898-6905.

Dixon KO, van der Kooij SW, Vignali DA, van Kooten C: Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. European journal of immunology 2015, 45(6):1736-1747.

Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C et al: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507(7492):366-370.

Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH, Egwuagu CE: Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014, 20(6):633-641.

Sha X, Meng S, Li X, Xi H, Maddaloni M, Pascual DW, Shan H, Jiang X, Wang H, Yang XF: Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway. J Biol Chem 2015, 290(31):19307-19318.

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA et al: IL-35-mediated induction of a potent regulatory T cell population. Nature immunology 2010, 11(12):1093-1101.

Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European journal of immunology 2007, 37(11):3021-3029.

Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF: Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011, 141(5):1875-1886.

Dong J, Wong CK, Cai Z, Jiao D, Chu M, Lam CW: Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells. Allergy 2015, 70(8):921-932.

Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA: Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012, 61(6):1519-1526.

Devergne O, Birkenbach M, Kieff E: Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(22):12041-12046.

Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, Li X, Sellati R, Jiang H, Zhang S, Li H et al: Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. European journal of immunology 2008, 38(5):1204-1214.

Frank GM, Divito SJ, Maker DM, Xu M, Hendricks RL: A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis. Invest Ophthalmol Vis Sci 2010, 51(7):3591-3598.

Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA: IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res 2003, 23(9):513-522.

Bettini M, Vignali DA: Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009, 21(6):612-618.

Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA: Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011, 186(12):6661-6666.

Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG et al: The composition and signaling of the IL-35 receptor are unconventional. Nature immunology 2012, 13(3):290-299.

Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2):133-146.

Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T: Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol 1992, 148(12):4066-4071.

Floss DM, Schonberg M, Franke M, Horstmeier FC, Engelowski E, Schneider A, Rosenfeldt EM, Scheller J: IL-6/IL-12 Cytokine Receptor Shuffling of Extra- and Intracellular Domains Reveals Canonical STAT Activation via Synthetic IL-35 and IL-39 Signaling. Sci Rep 2017, 7(1):15172.

Wu S, Li Y, Yao L, Li Y, Jiang S, Gu W, Shen H, Xia L, Lu J: Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes. Clin Exp Rheumatol 2017.

Liu H, Zhang W, Tian FF, Kun A, Zhou WB, Xiao B, Li J: IL-35 Is Involved in the Pathogenesis of Guillain-Barre Syndrome Through Its Influence on the Function of CD4+ T Cells. Immunol Invest 2015, 44(6):566-577.

Garbers C, Aparicio-Siegmund S, Rose-John S: The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 2015, 34:75-82.

Olson BM, Sullivan JA, Burlingham WJ: Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 2013, 4:315.

Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW: IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010, 184(12):7144-7153.

Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW, Chua KY: Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011, 187(1):462-471.

Espes D, Singh K, Sandler S, Carlsson PO: Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide. Diabetes Care 2017, 40(8):1090-1095.

Collison LW, Pillai MR, Chaturvedi V, Vignali DA: Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009, 182(10):6121-6128.

Zhang J, Lin Y, Li C, Zhang X, Cheng L, Dai L, Wang Y, Wang F, Shi G, Li Y et al: IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis. J Immunol 2016, 197(6):2131-2144.

Wang Y, Mao Y, Zhang J, Shi G, Cheng L, Lin Y, Li Y, Zhang X, Zhang Y, Chen X et al: IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med 2018, 22(2):1014-1025.

Mo L, Chen Q, Zhang X, Shi X, Wei L, Zheng D, Li H, Gao J, Li J, Hu Z: Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer. Vaccine 2017, 35(43):5932-5938.

Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DA: Interleukin-35 Limits Anti-Tumor Immunity. Immunity 2016, 44(2):316-329.

Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5(7):521-531.

Liang Y, Chen Q, Du W, Chen C, Li F, Yang J, Peng J, Kang D, Lin B, Chai X et al: Epstein-Barr Virus-Induced Gene 3 (EBI3) Blocking Leads to Induce Antitumor Cytotoxic T Lymphocyte Response and Suppress Tumor Growth in Colorectal Cancer by Bidirectional Reciprocal-Regulation STAT3 Signaling Pathway. Mediators Inflamm 2016, 2016:3214105.

Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B et al: Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol 2013, 6(9):1806-1816.

Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L, Shen L: Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget 2016, 7(45):73003-73015.

Wang K, Gong H, Chai R, Yuan H, Chen Y, Liu J: Aberrant frequency of IL-35 producing B cells in colorectal cancer patients. Cytokine 2018, 102:206-210.

Zhang J, Mao T, Wang S, Wang D, Niu Z, Sun Z, Zhang J: Interleukin-35 expression is associated with colon cancer progression. Oncotarget 2017, 8(42):71563-71573.

Guo B, Zhang R: Statistical Methods for Clinical Trial Designs in the New Era of Cancer Treatment. Biostat Biom Open Access J 2018, 5(3).

Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, Carter CR: Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 2013, 108(5):997-1003.

Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, Wei XQ: IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013, 430(1):364-369.

Nicholl MB, Ledgewood CL, Chen X, Bai Q, Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ, Fang Y: IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine 2014, 70(2):126-133.

Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J: Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Human immunology 2014, 75(1):29-33.

Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y, Bai XF: Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013, 190(5):2415-2423.

Rasko JEJ, Hughes TP: First Approved Kinase Inhibitor for AML. Cell 2017, 171(5):981.

Sander FE, Nilsson M, Rydstrom A, Aurelius J, Riise RE, Movitz C, Bernson E, Kiffin R, Stahlberg A, Brune M et al: Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunol Immunother 2017, 66(11):1473-1484.

Rooney CM: Can Treg elimination enhance NK cell therapy for AML? Blood 2014, 123(25):3848-3849.

Wu H, Li P, Shao N, Ma J, Ji M, Sun X, Ma D, Ji C: Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett 2012, 3(5):1119-1123.

Wang J, Tao Q, Wang H, Wang Z, Wu F, Pan Y, Tao L, Xiong S, Wang Y, Zhai Z: Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia. Human immunology 2015, 76(9):681-686.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K et al: Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014, 123(25):3855-3863.

Tao Q, Pan Y, Wang Y, Wang H, Xiong S, Li Q, Wang J, Tao L, Wang Z, Wu F et al: Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int J Cancer 2015, 137(10):2384-2393.

Vinayak R, Cruz RJ, Jr., Ranganathan S, Mohanka R, Mazariegos G, Soltys K, Bond G, Tadros S, Humar A, Marsh JW et al: Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015). Liver Transpl 2017, 23(12):1577-1588.

Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, Chung AY, Jooi LL, Lee CG: Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010, 53(1):57-66.

Fares N, Peron JM: [Epidemiology, natural history, and risk factors of hepatocellular carcinoma]. Rev Prat 2013, 63(2):216-217, 220-212.

Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y et al: Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer 2016, 114(7):767-776.

Long J, Guo H, Cui S, Zhang H, Liu X, Li D, Han Z, Xi L, Kou W, Xu J et al: IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression. Oncotarget 2016, 7(29):45678-45686.

Gao J, Song Z, Chen Y, Xia L, Wang J, Fan R, Du R, Zhang F, Hong L, Song J et al: Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis 2008, 40(2):114-121.

Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR: Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006, 44(2):446-457.

Li H, Zhang YX, Liu Y, Wang Q: Effect of IL-17 monoclonal antibody Secukinumab combined with IL-35 blockade of Notch signaling pathway on the invasive capability of hepatoma cells. Genet Mol Res 2016, 15(2).

Tessmer MS, Flaherty KT: AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives. Clin Cancer Res 2017, 23(18):5325.

Schirrmeister H: Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007, 45(4):669-676, vi.

Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, Chen C, Huang M, Chen J, Wu W et al: Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. American journal of translational research 2016, 8(5):2255-2264.

Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, Li M, Wang C, Mao H: Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine 2017, 89:76-81.

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N et al: Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011, 17(19):6272-6286.

Jiang S, Li Y, Lin T, Yuan L, Li Y, Wu S, Xia L, Shen H, Lu J: IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis. Cell Physiol Biochem 2016, 40(5):1105-1116.

Zhou C, Zhang J, Chen Y, Wang H, Hou J: Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Onco Targets Ther 2017, 10:3485-3491.

Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG: Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012, 189(12):5590-5601.

Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, Guo Y, Fan K: Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2015, 36(4):2651-2656.




DOI: http://dx.doi.org/10.30564/amor.v4i3.177

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Junfeng Zhang, Yunsheng Zhang, Chunlei Li, Xiaomei Zhang, Huabao Xiong, Hongxin Deng

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.